This suggests that PIK3CA activation is involved in paclitaxel resistance and may thus be a clinically relevant target to overcome chemoresistance and prevent metastasis during paclitaxel chemotherapy in cervical cancer. This evidence concerns the gene PIK3CA and cervical carcinoma.